| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BLID |
| Uniprot No | Q8IZY5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-108aa |
| 氨基酸序列 | MVTLLPIEGQEIHFFEILESECVLYTGWIERASGSSIYPEAKARLPLEALLGSNKEPMLPKETVLSLKRYNLGSSAMKRNVPGHVLQRPSYLTRIQVTLLCNSSAEAL |
| 预测分子量 | 39.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BLID重组蛋白的3篇参考文献示例(注：部分文献信息为模拟概括，实际引用时请核实原文)：
---
1. **文献名称**：*"Pro-apoptotic BH3-only protein BLID regulates apoptosis through interaction with Bcl-2 family proteins"*
**作者**：Chen Y, et al.
**摘要**：本研究成功在大肠杆菌中表达并纯化了重组BLID蛋白，验证其通过BH3结构域与抗凋亡蛋白Bcl-xL相互作用，激活线粒体凋亡通路。体外实验表明，BLID重组蛋白可诱导癌细胞凋亡，提示其潜在抗肿瘤应用价值。
2. **文献名称**：*"Structural and functional characterization of recombinant human BLID: insights into its role in caspase activation"*
**作者**：Wang L, et al.
**摘要**：通过原核系统表达BLID重组蛋白，结合X射线晶体学解析其三维结构，揭示了其BH3结构域的关键氨基酸残基。功能实验证实，BLID重组蛋白通过激活caspase-9/caspase-3级联反应促进细胞凋亡。
3. **文献名称**：*"BLID knockdown enhances chemosensitivity by modulating mitochondrial apoptosis pathways in colorectal cancer"*
**作者**：Liu R, et al.
**摘要**：研究利用重组BLID蛋白进行体外补充实验，发现其可逆转化疗药物耐药性。机制分析表明，BLID通过调控Bax/Bak蛋白构象变化，诱导线粒体膜电位崩溃，从而增强结直肠癌细胞对5-FU的敏感性。
---
**说明**：以上文献为示例性内容，实际研究中请通过PubMed、Web of Science等平台以关键词“BLID recombinant protein”或“BLID apoptosis”检索最新文献，并核实作者及摘要准确性。若研究较少，可扩展至BH3-only蛋白家族或凋亡机制相关研究。
**Background of BLID Recombinant Protein**
BLID (BCL2-like 1-deficient in apoptosis) is a protein encoded by the *BLID* gene, initially identified as a pro-apoptotic member of the BCL-2 protein family. This family regulates mitochondrial apoptosis by balancing pro-survival (e.g., BCL-2. BCL-XL) and pro-apoptotic (e.g., BAX, BAK) members. BLID contains a conserved BH3 domain, critical for initiating apoptosis by interacting with anti-apoptotic BCL-2 proteins, thereby neutralizing their function and promoting cytochrome c release from mitochondria.
The *BLID* gene is located on chromosome 11q24.1 and is epigenetically silenced in certain cancers, linking its loss to tumor progression and chemoresistance. Studies suggest BLID expression correlates with improved survival in cancers like ovarian and gastric carcinoma, highlighting its role as a tumor suppressor.
Recombinant BLID protein is engineered using expression systems (e.g., *E. coli* or mammalian cells) to produce functional, purified protein for research. Its applications include elucidating apoptotic mechanisms, screening for drugs targeting BCL-2 family interactions, and studying epigenetic regulation in cancer. BLID recombinant protein also aids in structural studies to map binding interfaces with anti-apoptotic proteins, informing therapeutic design.
Despite its significance, BLID’s regulatory mechanisms and tissue-specific roles remain under investigation. Research continues to explore its interplay with other apoptotic factors and potential as a biomarker or therapeutic target. The development of BLID recombinant protein thus provides a vital tool for advancing apoptosis-related biomedical research and cancer therapy strategies.
(Word count: 247)
×
